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cause of the scar tissue developing after
the first intervention. However, in subse-
quent years, they were shown to be tech-
nically feasible also after induction chemo-
therapy. The most recent updated series of
redo mediastinoscopy after induction che-
motherapy are summarized in Table 12-5
and compared with the overall results of
restaging by means of PET/CT in the study
of Cerfolio and coworkers.1 The latter data
were extracted from Figure 2 and not re-
ported as such by the authors. Published
mortality and morbidity rates of redo me-
diastinoscopy are very low. Its main ad-
vantage consists of providing histologic
evidence of mediastinal downstaging in
contrast to the pure anatomic and histo-
logic data given by means of PET/CT.
Moreover, Cerfolio and coworkers advo-
cate the use of maxSUV of the primary
tumor and involved lymph nodes. In con-
trast to what its name suggests, maxSUV
is not standardized among different PET
scanners and centers, making comparison
and adoption of the proposed values by
other institutions impossible. Also, the
high cost of PET/CT is not addressed by
the authors.
The very interesting data coming from
the EUS-FNA series pave the way for
a constructive discussion. An alternative
strategy to avoid redo mediastinoscopy
consists of initial proof of mediastinal node
involvement by means of EUS-FNA, fol-
lowed by induction chemotherapy and, af-
terward, mediastinoscopy to evaluate me-
diastinal response. In this way a technically
more demanding redo mediastinoscopy can
be avoided by thoracic surgeons having no
experience with this technique. We would
appreciate the authors’ comments on these
remarks.
Pierluigi Granone, MDa
Paul Van Schil, MDb
Alfredo Cesario, MDa,c
Department of Thoracic Surgerya
Catholic University
Rome, Italy
Department of Thoracic and Vascular Surgeryb
University Hospital of Antwerp
Edegem, Belgium
Department of Internal Medicine and Cardio-
Pulmonary Rehabilitationc
IRCCS San Raffaele
Rome, Italy
References
1. Cerfolio RJ, Bryant AS, Buddhiwardhan O.
Restaging patients with N2 (stage IIIa) non-
small cell lung cancer after neoadjuvant che-
moradiotherapy: a prospective study. J Tho-
rac Cardiovasc Surg. 2006;131:1229-35.
2. Pitz CC, Maas KW, van Swieten HA, de la
Riviere AB, Hofman P, Schramel FM. Sur-
gery as part of combined modality treatment
in stage IIIB non-small cell lung cancer. Ann
Thorac Surg. 2002;74:164-9.
3. Rami-Porta R, Mateu-Navarro M, Serra-
Mitjans M, Hernandez-Rodriguez H. Reme-
diastinoscopy: comments and updated results.
Lung Cancer. 2003;42:363-4.
4. Stamatis G, Fechner S, Hillejan L, Hintherthaner
M, Krbek T. Repeat mediastinoscopy as a restag-
ing procedure. Pneumologie. 2005;59:862-6.
5. De Waele M, Hendriks J, Lauwers P, Ort-
manns P, Vanroelen W, Morel AM, et al.
Nodal status at repeat mediastinoscopy deter-
mines survival in non-small cell lung cancer
with mediastinal nodal involvement, treated
by induction therapy. Eur J Cardiothorac
Surg. 2006;29:240-3.
doi:10.1016/j.jtcvs.2006.06.049
Reply to the Editor:
Dr Cesario and colleagues have posed some
important and interesting questions con-
cerning the role of repeat mediastinoscopy
after induction radiotherapy. We need to
limit our comments to patients who have
had radiotherapy because that is the real
issue and not those who had chemotherapy
alone. The authors state that “pathologic
reassessment of the mediastinum is strongly
advisable,” and we, as our article clearly
outlines, agree. The table the authors show
compares a clinical staging modality, pos-
itron emission tomography (PET)/computed
tomography with a pathologic staging pro-
cedure (repeat mediastinoscopy). As we
have preached and written, pathologic stag-
ing always trumps clinical staging,1 and
thus this comparison is unjustified. Repeat
PET/computed tomography directs biop-
sies by providing targets for biopsy, as we
clearly state. The question is as follows:
What is the safest and most accurate way to
achieve rebiopsy of previously cancerous
N2 mediastinal lymph nodes after induc-
tion chemoradiotherapy? Although there is
little doubt that repeat mediastinoscopy can
be performed safely (as we have done sev-
eral times ourselves), we do not recom-
mend it on a national basis nor do we
believe it is accurate in most surgeons’
hands. The authors are biased by their own
skill and might not realize that the vast
majority of these patients are not seen by
surgeons who have their type of expertise.
If we send out the message that repeat
mediastinoscopy after radiotherapy is safe
and accurate or is “the standard of care,” I
fear the subsequent morbidity and even
mortality that might ensue. A large number
of patients in the United States with lung
cancer receive their surgical care from less-
experienced hands than those of Drs Gra-
none, Schil, and Cesario. The message
from our literature must take this fact into
account. I do not believe that repeat medi-
astinoscopy after chest irradiation is safe or
accurate in the typical center. In fact, al-
though it might be safe in select hands, the
accuracy is still in doubt. Careful analysis
of the articles referenced by the authors’
letter shows the relatively high morbidity
for mediastinoscopy for those who had ra-
diotherapy (not chemotherapy alone). Thus
TABLE 1. Results of redo mediastinoscopy after induction chemotherapy compared with results of PET/CT1-5
Author, year No. of patients IT
Morbidity
(%)
Mortality
(%)
Sensitivity
(%)
Specificity
(%)
Accuracy
(%)
Cerfolio and coworkers, 20061 (PET/CT study) 93 CT-RT 0 0 62 88 79
Pitz and coworkers, 20022 15 CT 0 0 71.4 100 87
Rami-Porta and coworkers, 20033 24 CT 0 0 83 100 91
Stamatis and coworkers, 20054 165 CT-RT 2.5 0 74 100 93
De Waele and coworkers, 20065 32 CT (26)
CT-RT (6)
3.1 0 71 100 84
IT, Induction therapy; CT-RT, chemoradiotherapy; CT, chemotherapy.
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we continue to recommend rebiopsy of
the 2R, 4R, and 4L stations through thora-
cotomy or through video-assisted thoraco-
scopic surgery.
The authors’ second question concerns
the oxymoronic nature of the term standard-
ized uptake value or maximum standardized
uptake value (maxSUV). The authors state
that “maxSUV is not standardized among
different PET scanners and centers, mak-
ing comparison and adoption of the pro-
posed values by other institutions impossi-
ble.” We strongly but amicably disagree
with this statement. First, the percentage
change takes into account most of these
variables, and this is why we recommend
the repeat PET scan to be performed at the
same center using the same techniques as
the initial staging PET scan. Second, after
much investigation and discussion with
PET engineers, designers, and technicians,
as well as expert nuclear radiologists,
across the world, we are told that the dif-
ference in the maxSUV of a patient’s can-
cer on a PET scanner in Italy might only be
up to 20% different if the patient had been
scanned in Birmingham, Alabama. It is true
that 20% is not negligible, but this is the
upper end of the discrepancy. Many steps
have already been implemented to limit
these differences and to promote the stan-
dardization of the PET techniques and thus
the maxSUV values. Finally, because we
recognized this as a possible limitation to
the everyday clinical applicability of our
data, our future studies, some of which
have been completed, have focused on
ways to account for these differences. For
instance, in this article we use the percent-
age change of the maxSUV of the primary
tumor and of the involved mediastinal
lymph node. We also have studied the use of
the ratio of the maxSUV of the tumor to the
N2 nodes to help predict metastatic disease.
When that ratio is 0.6 or greater, there is an
85% chance the node is malignant, and this
holds true for many different centers.2 This
obviates the need for absolute values and
takes into account the differences in max-
SUVs across different centers. Finally, we
are also studying the ratio of the size of the
tumor to the maxSUV value of the tumor.
The third and final question posed con-
cerns the increasing use of endoscopic
ultrasonography–guided fine-needle aspi-
ration (EUS-FNA). We have studied and
written extensively on EUS-FNA3,4 and
have used it as our first line of biopsy for
N2 nodal biopsy in patients who have sus-
picious lymph nodes metastasis in posterior
(7, 8, and 9) stations. Since 2001, we have
used EUS-FNA first so as to reserve the
mediastinoscopy for after induction che-
moradiotherapy. We also use repeat EUS-
FNA in those patients as well, as we have
described in our articles. However, the au-
thors did not note the downside of this
strategy, which is that one might miss un-
suspected N3 disease initially by not using
mediastinoscopy. The incidence of unsus-
pected N3 disease is higher in patients with
multinodal N2 disease as well. Finally,
EUS-FNA is great for the 7, 8, and 9 sta-
tions but is blind in most endosonogra-
pher’s hands for the 2R, 4R, 2L, 5, and
6 stations. I greatly appreciate the authors’
thoughtful and insightful letter, and I agree
with the majority of their comments.
Robert J. Cerfolio, MD
Cardiothoracic Surgery
University of Alabama at Birmingham
Birmingham, AL
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Ascending– descending aortic
bypass with the aid of a
heart-lifting device
To the Editor:
We read with interest the article “Ascending–
descending aortic bypass with the aid of a
heart-lifting device” by Aris and associ-
ates.1 We had an opportunity to use the
technique in the management of a 15-year-
old girl. She had arch reconstruction with
pulmonary artery banding through a tho-
ractomy at the age of 8 months for type B
interruption with ventricular septal defect.
Six months after the procedure, she had
undergone pulmonary artery debanding
with ventricular septal defect closure. She
had narrowing across the arch repair site,
with a gradient of 80 mm Hg across the
stenosed segment and significant left ven-
tricular hypertrophy.
In view of her previous operation, it
was decided to perform ascending–de-
scending aortic bypass during cardiopul-
monary bypass with a beating heart. An
18-mm Dacron tube graft was anastomosed
to the descending aorta with a heart-lifting
device (Starfish 2; Medtronic, Inc, Minne-
apolis, Minn) to keep the ventricular mass
out of the way during the operation (Figure
1). The descending aorta was approached
from the posterior pericardium. The stays
on the margins of the pericardium can also
be used to provide additional retraction
during exposure. We placed the graft lat-
eral to the right atrium within the pericar-
dium because we considered that the lie of
the graft would be better in this position.
The patient had uneventful postoperative
recovery with no residual gradient between
the upper and lower limbs at the time of
discharge.
Other techniques have been described
for performing bypass in the management
of complex recoarctation. The lateral
isthmic bypass2 between the left subcla-
vian artery and the descending aorta has
the advantage of being an “anatomic”
bypass. The disadvantage of the tech-
nique in our patient was that it would
require a repeat thoracotomy, and there
Figure 1. Use of the Starfish 2 device
(Medtronic, Inc) for ascending–descending
aortic bypass for retracting the ventricle.
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